3Helix, Inc.
StreetZero Signal 74
About 3Helix, Inc.
3Helix, Inc. is a biotechnology company founded in 2015 and headquartered in Salt Lake City, Utah. It develops Collagen Hybridizing Peptide (CHP) technology that targets damaged and denatured collagen for applications in fibrosis, inflammation, wound healing, tissue engineering, and personal care. The company has advanced bioACTIVE CHP platforms to modulate collagen-driven processes and activate rejuvenation mechanisms. Its mission is to translate breakthrough science on damaged collagen into life-changing medicines.
LATEST FUNDINGPrivate Placement
$7.8M
Announced 2026-09-21
TOTAL RAISED$3.75M
IN THE NEWS
- 🔗 3Helix 2026 Company Profile: Valuation, Funding & Investors | PitchBook
- 🔗 3Helix, Inc. - Enabling transformative breakthroughs by targeting damaged collagen
- 🔗 Ballard Spahr Advises 3Helix in Funding Round Led by BASF | News | Insights | Ballard Spahr
- 🔗 BASF invests in start-up 3Helix Inc. to jointly bring collagen-hybridizing peptide solutions to the personal care market
- 🔗 BASF invests in start-up 3Helix Inc. to jointly bring collagen-hybridi
EMPLOYEES2-10
FOUNDED2015
HQSalt Lake City, UT, United States
Industry
Biotechnology
Tags
BiotechnologyCollagenPeptidesTherapeutics
Key highlights
- Raised $3.75M Seed round with seven investors including BASF.
- Secured BASF equity investment and exclusive license for personal care applications of CHP technology.
- Founded by biomedical engineering professors Dr. Michael Yu and Dr. Yang Li.
- Pioneered first platform exploiting structural differences between damaged and healthy collagen.
- Headquartered in Salt Lake City with focus on fibrosis, wound healing, and extracellular matrix research.
Ask StreetZero about 3Helix, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account